[AF] WHO Pharmaceuticals Newsletter No.2, 2006

[Martín Cañás]

Estimadas y estimados,

Se publicó el WHO Pharmaceuticals Newsletter No. 2, 2006 con el siguiente
indice:

Regulatory Matters
Adalimumab, Etanercept, Infliximab -- Linked to HBV reactivation..1
Atomoxetine -- New warnings recommended ......................... 1
Bevacizumab -- Label to include information onPLS.................2
Bosentan -- Label to indicate liver adverse effects .... 2
Gatifloxacin -- Reinforced warnings in Canada, labelling changes in US.. 2
Hydroxycarbamide -- Label to include information on cutaneousvasculitis... 2
Ximelagatran -- Withdrawn due to adverse liver effects... 3

Safety of Medicines
Aprotinin -- Reports of serious cardiovascular, cerebrovascular and kidney
effects .... 4
Benzocaine -- Mouth and throat use linked with methaemoglobinaemia... 4
Ergot derivatives -- Reports of fibrotic complications .......4
Fluoroquinolones -- Interactions with warfarin .... 5
Methyl-1-testosterone -- Reports of serious health risks...5
Nimodipine -- Warning against intravenous use of capsules... 5
Pegaptanib -- Allergic reactions reported... 5
Rosiglitazone -- Reports of parotid gland enlargement... 6
Selegeline -- Confusion with brand name Salagen... 6
Feature
We should not say 'drug safety' when we mean 'drug toxicity'... 7

 esta disponible en:
http://www.who.int/entity/medicines/publications/2006News2%20.pdf



Saludos,

Maríin

Martín Cañás
GAPURMED La Plata (Argentina)
macanas en netverk.com.ar
_______________________________________________